It has been reported that combination therapy targeting the PD‐1/PD‐L1 axis and NKG2A (with monalizumab), enhanced NK cell activity by increasing degranulation and IFN‐γ production, and rescued CD8 T cell function in various cancer models [4]. Here, KLRC1 is linked to cancer.